Please use this identifier to cite or link to this item:
|Title:||Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction||Authors:||Yeo, K.P.
Protein kinase C β
|Issue Date:||Feb-2006||Citation:||Yeo, K.P., Lowe, S.L., Lim, M.T., Voelker, J.R., Burkey, J.L., Wise, S.D. (2006-02). Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction. British Journal of Clinical Pharmacology 61 (2) : 200-210. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1365-2125.2005.02540.x||Abstract:||Aims: The aim of this study was to evaluate the effect of rifampicin co-administration on the pharmacokinetics of ruboxistaurin and its active metabolite, N-desmethyl ruboxistaurin and, in addition, to compare the changes in pharmacokinetics of ruboxistaurin and N-desmethyl ruboxistaurin with the urinary 6β-hydroxycortisol:cortisol ratio. Ruboxistaurin is a specific protein-kinase-C β inhibitor in clinical development for the treatment of diabetic microvascular complications. Methods: This was a two-period, one-sequence study. Sixteen healthy male subjects completed both study periods. In period one, a single 64 mg oral dose of ruboxistaurin was administered. In period two, 600 mg rifampicin was administered daily for 9 days, during which another single 64 mg ruboxistaurin dose was administered on day 7. Blood samples were collected and assayed for ruboxistaurin and N-desmethyl ruboxistaurin. CYP3A4 induction was assessed by ratios of urinary 6β-hydroxycortisol: cortisol (6β-OHC:C) obtained via 24 h and morning-spot sampling techniques. Results: Following repeated doses of rifampicin, both the mean Cmax and AUC(0,∞) of ruboxistaurin were significantly reduced by approximately 95% (P ≤ 0.001). For the metabolite, the mean Cmax decreased by 68% (P ≤ 0.001), and AUC(0,∞) decreased by 77% (P ≤ 0.001). The tmax values did not appear affected. The 6β-OHC:C ratios from both 24 h and morning spot methods increased significantly, consistent with CYP3A4 induction. Conclusions: The effect of rifampicin co-administration on the exposure of ruboxistaurin is consistent with ruboxistaurin being a substrate of CYP3A4. Therefore, co-administration with known CYP3A4 inducing agents (rifampicin, carbamazepine, phenobarbital, etc.) may decrease the concentrations of ruboxistaurin and N-desmethyl-ruboxistaurin. In this study, 6β OHC:C ratios substantially underestimated the impact of rifampicin on ruboxistaurin. © 2005 Blackwell Publishing Ltd.||Source Title:||British Journal of Clinical Pharmacology||URI:||http://scholarbank.nus.edu.sg/handle/10635/112011||ISSN:||03065251||DOI:||10.1111/j.1365-2125.2005.02540.x|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 21, 2021
WEB OF SCIENCETM
checked on Oct 13, 2021
checked on Oct 14, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.